Financial toxicity following cancer treatment is increasingly prevalent. Evidence suggests that few families can afford unexpected expenses exceeding $400, and even small increases in out-of-pocket costs are associated with treatment nonadherence,1 potentially widening nationally recognized societal disparities in cancer treatment and survival. High costs may render cancer care unaffordable for the individual patient who is uninsured or underinsured. Despite growing economic and health gaps, a coordinated nationwide policy approach, one that supports clinicians and patients, to curbing cancer’s (as well as other conditions’) financial burden is lacking.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Bradley CJ, Yabroff KR, Shih YT. A Coordinated Policy Approach to Address Medical Financial Toxicity. JAMA Oncol. Published online October 21, 2021. doi:10.1001/jamaoncol.2021.3606
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.